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Child-Friendly version of EQ-5D will be discussed to realize the
ﬁnal version of the questionnaire.
PIH15
DEVELOPMENT OF AN ICIQ NOCTURNAL ENURESIS 
QOL QUESTIONNAIRE
Holm-Larsen T1, Hansson M2, Riis A2, Gennaro M3, Hagstrom S4,
Nørgaard JP5
1University of Pharmaceutical Sciences, Copenhagen, Denmark,
2Ferring Pharmaceuticals A/S, Copenhagen, Denmark, 3Bambino Gesù
Children’s Hospital, Rome, Italy, 4Hospital of Skejby, Aarhus, Denmark,
5Ferring Pharmaceuticals, Copenhagen, Denmark
OBJECTIVES: There is a lack of a validated QoL questionnaire
assessing the psychological burden and treatment beneﬁts of bed-
wetting as evaluated by the child. This abstract reports the results
of the initial validation tests for such a questionnaire. It is being
developed in accordance with the validation standards of the
ICIQ. METHODS: A literature review was conducted and led
to quantitative interviews with 28 children suffering from Noc-
turnal Enuresis and 28 pairs of parents. Consequently a ques-
tionnaire including 20 questions was developed and tested in a
multinational Randomised Clinical Trial completed by 196 chil-
dren and 196 parents in antidiuretic treatment before and during
the trial. RESULTS: Based on review and interviews, a list of
issues was identiﬁed: Social isolation, emotional distress, low
self-esteem, problems in parent-child relation, delayed indepen-
dence and fear of being teased at school and home. Two or more
questions were developed for each of the six issues to add room
for elimination of poorly performing questions. The RCT data
indicated promising cluster effect, i.e. the well treated children
showed a high QoL, and the questions seemed test-retest con-
sistent. Some questions yield a high level of missing answers.
CONCLUSION: The tests led to reformulation of the questions
yielding missing answers and the questionnaire is now ready for
the coming validation, including sensitivity analysis and item
reduction. We are convinced that future research in Nocturnal
Enuresis will proﬁt from the ﬁnal questionnaire.
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OBJECTIVE: Duration of vaginal estrogen therapy (VET) may
vary. This study sought to compare and contrast treatment dura-
tion of women prescribed vaginal tablets (VT) or vaginal creams
(VC) in clinical trials with that in clinical practice. METHODS:
Adults initiating VET between January and June, 2004 in 57
managed care plans (PharMetrics database) in the United States
were identiﬁed and followed for up to 10 months to examine
their treatment duration. A Kaplan-Meier analysis was per-
formed to obtain average and median time to discontinuation
for individuals treated with VT or VC. A weighted average of
treatment duration was calculated for a total of seven clinical
trials identiﬁed in the literature. These results were stratiﬁed by
study inclusion criteria. Differences in average treatment duara-
tion were statistically tested using t-tests. RESULTS: Of 5599
patients undergoing VET (mean age = 54 ± 9.1 years), 4355
(77.8%) received VC and 1244 (22.2%) received VT. Patients
prescribed VT had a signiﬁcantly longer average (median) treat-
ment compared to patients prescribed VC [(198.5 ± 82.4 days
(221 days) vs. 177.1 ± 86.7 days (190 days)); p < 0.01)]. This
duration in clinical practice was signiﬁcantly longer than that in
seven clinical trials [165 days (240 days for three trials of both
VC and VT; 90 days for two VT-only studies; and 69 days for
two VC-only studies)]. CONCLUSIONS: Duration of VET was
longer in a real-world clinical practice setting than in clinical
trials. Moreover, subjects treated with VT exhibited signiﬁcantly
longer treatment duration than subjects treated with VC. Possi-
ble factors explaining longer duration with VT include ease of
use, reduced messiness, accurate dosing resulting in improved
effectiveness and fewer adverse events, and consequently
improved quality of life. Future studies should prospectively
examine factors associated with these differences.
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OBJECTIVES: Nocturnal enuresis (NE) can pose signiﬁcant psy-
chological burden on children’s self-esteem and quality of life
(QoL). Therefore, patient-reported outcome (PRO) measure-
ment is essential to fully understand the burden posed by NE
and the beneﬁts of treating this condition. To our knowledge, it
has not been investigated which instruments should be used to
assess the psychological burden of NE. The aim of this study was
to identify and evaluate PRO instruments used in children with
NE. METHODS: A literature search of Medline and other data-
bases was conducted to identify publications from 1995–2006
which contained PRO instruments used in children with NE.
RESULTS: 40 studies and 32 PRO instruments were identiﬁed.
Instruments were evaluated based on psychometric properties
and responsiveness to change. Some studies used several PRO
instruments. The Child Behavior Checklist was the most 
commonly used instrument (8/40 studies, 20%). Measures of
self-esteem were used in 11/40 studies (28%). No generic QoL
measures were used in these trials. No disease-speciﬁc PRO
instruments were found to be fully validated in the NE. popula-
tion. Currently, a new disease-speciﬁc QoL questionnaire is in
development for NE. CONCLUSIONS: The results of this study
highlight the lack of patient-reported disease-speciﬁc PRO mea-
sures to assess the burden and treatment beneﬁts of NE. A new
disease-speciﬁc instrument may be able to ﬁll this gap.
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OBJECTIVES: To compare Finnish patients with erectile dys-
function (ED) and men from the Finnish general population in
measures of self-reported Health-Related QOL (HRQoL) and
satisfaction with life, and to investigate whether switching
patients from current oral ED medication to tadalaﬁl impacts
these measures. METHODS: A total of 202 Finnish men over
18 years successfully treated with oral ED prescription medica-
tion (tadalaﬁl excluded) voluntarily entered this multicenter,
open-label, one-arm, 3-month study. Upon enrollment, patients
discontinued their previous therapy and were started on tadalaﬁl
10 or 20 mg (dose determined by investigator) on demand.
Outcome was measured using the 15D and Life Satisfaction-11
(LiSat-11) checklists. 15D is a generic, comprehensive, 15-
dimensional, standardized, self-administered measure of HRQoL
